Glaxo signs early drug discovery deal with Biotica

Mon Jan 12, 2009 8:53am GMT
 
Email | Print | | Single Page
[-] Text [+]

LONDON (Reuters) - GlaxoSmithKline (GSK.L) has signed a three-year drug discovery deal with privately held biotech company Biotica Technology, giving the drugmaker access to Biotica's early-stage work in inflammatory diseases.

Biotica said on Monday it would receive an initial cash payment and up to 86 million pounds ($129.6 million) for each compound successfully developed.

Glaxo has also made an upfront equity investment in Biotica.

The collaboration focuses on novel erythromycin-based macrolide compounds for treating unspecified inflammatory diseases. These compounds have yet to reach the pre-clinical development stage, according to Biotica's website, which means they are still many years from hitting the market.

Biotica's most advanced research is in a group of compounds known as rapamycin analogues, where it is working with Wyeth WYE.N.

(Reporting by Ben Hirschler; Editing by Jon Loades-Carter)

 
A pedestrian passes a Vodafone store on Oxford Street in central London, November 10, 2009. REUTERS/Kevin Coombs
Telecoms set for take-off?

European telecoms are undervalued and companies such as Telefonica and Vodafone could rise 25 to 30 percent in the next year, says a fund manager at BlackRock.  Full Article 

Market Update

  • UKUK
  • USUS
  • Europe
  • Asia
  • UK Most Actives

Most Popular Business News on Reuters UK

  • Articles
  • Videos